Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
In this video, Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, briefly discusses the role of navtemadlin in the treatment of myeloproliferative neoplasms (MPNs) and the mechanism of action of this agent. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
Disclosures
Advisory boards for Novartis, Abbvie, BMS, AOP Orphan.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.